ClinicalTrials.gg
RecruitingNCT06501495MemoAgeUpdated Apr 13, 2026

Links Between Cognitive Deficits During Normal or Pathological Aging and Slow Waves Measured in EEG

An interventional study of video polysomnography and Attention task in Aging and Alzheimer Disease, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris — 9 open to participants now, 9 under way, 1 of them phase 3. Alzheimer Disease · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
8th of 14
90 · median 91
Started
2025
with 1 other
No phase
11 of 28
4 open now
Registered
24th of 28
by date

Among the 28 studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris, this one is the 8th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2025, is one of 11 with no phase, and was the 24th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

9 of the 28 studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

With age, memory processes (encoding, consolidation and retrieval) as well as daytime vigilance are altered. Sleep is also impaired in older adults, notably slow waves that are known to play a key role in memory consolidation. Interestingly, some slow waves can also be detected in EEG recordings during wakefulness, and have been related to vigilance fluctuations.

The investigators believe that slow waves, during both sleep and wakefulness, could constitute a common biomarker of sleep disturbances and daytime vigilance problems. A dysregulation of slow waves could thus explain the impact of aging on the different memory processes. Since alterations in memory capacity, attention, and sleep quality are further exacerbated in patients with Alzheimer's disease (AD), the investigators propose to study the links between aging (normal and pathological), sleep and daytime vigilance alterations, and their impacts on the different key stages of memory.

The investigators will examine the associations between slow waves and changes in memory and vigilance in normal and pathological aging by studying young adults, seniors without cognitive disorders, and patients with prodromal AD. By replaying sensory cues associated with learning material during sleep, the investigators will also evaluate the effectiveness of auditory stimulation during sleep to enhance memory consolidation in older adults without and without cognitive deficits.

Overall, this study aims to better understand the relationships between slow waves, aging, memory, and vigilance, providing insights into cognitive decline and potential interventions in aging and Alzheimer's disease.

Read the detailed description

Introduction Aging is accompanied by cognitive decline, particularly affecting memory functions. Additionally, both the quantity and quality of sleep decrease with advancing age, specifically altering sleep oscillations (such as slow waves) that are involved in the reactivation of memories and are thus central to memory consolidation.

Aging is also associated with difficulties in maintaining daytime vigilance, even after a period of rest, impacting cognitive function, including the encoding and retrieval of memories. Interestingly, recent studies have revealed the existence of sleep intrusions, in the form of slow waves, in wakefulness EEG recordings. These have been associated with subjective and objective markers of fatigue, predict transient lapses in attention, and are particularly present after sleep deprivation. the investigators believe that slow waves, during both sleep and wakefulness, could constitute a common biomarker of sleep disturbances and daytime vigilance problems. A dysregulation of slow waves (fewer during sleep, more during wakefulness) could thus explain the impact of aging on the three fundamental stages of the memory process (encoding, consolidation, and retrieval). Since alterations in memory capacity, attention, and sleep quality are further exacerbated in patients with Alzheimer's disease (AD), the investigators propose to study the links between aging (normal and pathological), sleep and daytime vigilance alterations, and their impacts on the different key stages of memory.

Aims Our main objective is to test the associations between slow waves (during sleep and wakefulness) and the alterations in memory and vigilance during normal and pathological aging by studying young adults, seniors without cognitive disorders, and patients of the same age with prodromal AD.

Additionally, the investigators aim to test the efficiency of targeted memory reactivation (TMR) in older adults with and without cognitive deficits. TMR is a technique that has been showed to boost memory consolidation in young adults and mice by replaying during sleep sensory cues that have been previously associated with the learning material.

Methods Participants To do so, the stydy will include three groups: young adults (18-35 y.o), older adults without cognitive deficits (65-80 y.o), and older adults of the same age and with cognitive deficits (patients with prodromal Alzheimer's disease). Prodromal stage of Alzheimer's disease diagnosis will be performed by trained neurologists at the at the Memory and Alzheimer's Disease Institute (IM2A) of the Pitié-Salpêtrière Hospital, according to international diagnostic criteria as a clinical phenotype of progressive amnestic syndrome of the hippocampal type, associated with biological markers of Alzheimer's disease from lumbar puncture (Aβ \< 600 pg/mL and ptau > 60 pg/mL). During their clinical follow-up at the IM2A, patients diagnosed with prodromal AD will be offered the opportunity to participate in the study, in agreement with their attending physician. Healthy volunteers (both young and elderly) will be recruited through public announcements via the Relay for Information on Cognitive Sciences (RISC), from patients' relatives, or through the Fondation Recherche Alzheimer. Participation of both patients and healthy individuals will be voluntary, free, and informed. Participants will be contacted (by phone or email) by one of the study investigators. They will be informed about the conduct and purpose of the research protocol.

Protocol All participants will spend 3 days in the Sleep Disorders Unit of the Salpêtrière Hospital, including two nights.

Day 1: Participants will arrive in the late afternoon and will be fitted with the sensors required for video-polysomnography to monitor vigilance and sleep stages throughout the experiment. Then, they will 1) complete an attention task (modified version of the Sustained Attention to Response Task, SART), 2) perform an associated memory task (old/new task) consisting on recognition of words they have seen in the SART task, and 3) their resting-state EEG activity will be recorded. They will sleep in the laboratory (night 1, without intervention).

Day 2: Participants will retake the word recognition task the morning after night 1. During the afternoon they will fill different sleep questionnaires to assess their subjective feeling about their sleep: Pittsburgh sleep quality index (PSQI), Epworth sleepiness scale and the REM Behavior Disorder Screening Questionnaire (RBDSQ), as well as the geriatric depression scale (GDS). In the late afternoon, they will perform the learning and test phases of the visuospatial memory task. They will then sleep in the laboratory (night 2, with TMR). During their slow-wave sleep, half of the sounds associated with the items from the visuospatial memory task will be replayed.

Day 3: Participants will once again perform the visuospatial memory test the morning after night 2.

03

Conditions studied

  • Aging
  • Alzheimer Disease

Browse trials for

Keywords

  • aging
  • Alzheimer's disease
  • sleep
  • memory
  • attention
  • slow
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

  • Common Inclusion Criteria for All Three Groups:

Male or female Signed Affiliated with a social security system Native French speakers Completed at least 7 years of schooling (minimum 9th grade level)

Specific Inclusion Criteria for Each Group:

Patients:

Age: 60 to 85 years Prodromal stage of Alzheimer's disease diagnosed according to international diagnostic criteria, characterized by a clinical phenotype of progressive amnesic syndrome of the hippocampal type, associated with biological markers of Alzheimer's disease 1) from lumbar puncture (Aβ \< 600 pg/mL and ptau > 60 pg/mL)or 2) amyloid PET (positron emission tomography), or 3) with positive plasma Alzheimer's biomarkers

Cognitively Healthy Seniors:

Age: 60 to 85 years Age and sex matched with the Patients group "Cognitively healthy" status defined by a score of ≥ 26 on the (Mini-Mental State Examination), a score of ≥ 16 on the BREF (Batterie Rapide d'Efficience Frontale), and a score of ≥ 8 on the 5-word test

Young Adults:

Age: 18 to 35 years Sex matched with the Patients group "Cognitively healthy" status defined by a score of ≥ 26 on the MMSE (Mini-Mental State Examination), a score of ≥ 16 on the BREF (Batterie Rapide d'Efficience Frontale), and a score of ≥ 8 on the 5-word test

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    young adults, older adults without cognitive deficits, prodromal Alzheimer's Disease

    young adults, older adults without cognitive deficits, prodromal Alzheimer's Disease

    Other: video polysomnography · Other: Attention task

Interventions

  • Othervideo polysomnography

    video polysomnography during 2 nights

  • OtherAttention task

    Attention task : SART Test (Sustained Attention to Response Task)

06

What researchers measure

Primary outcomes

  1. slow waves density

    quantifying slow waves with their density (during sleep, wakefulness at rest and during tasks)

    Time frame: 2 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Apr 2027, 24 months after the start.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 24 months is below that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2024
First posted
Jul 15, 2024
StartActual
Apr 24, 2025
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06501495
Responsible party
Sponsor
First posted
Jul 15, 2024
Start date
Apr 24, 2025
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Apr 13, 2026

Study contacts

Marc Teichmann, MD
Contact
marc.teichmann@aphp.fr
01 42 16 75 34
Pierre Champetier, PhD
Contact
pierre.champetier@icm-institute.org
06 83 92 02 39
Marc Teichmann, MD
principal investigator · assisitance publique Hôpitaux de paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion